查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1848803

早产和胎膜早破检测市场（按产品类型、最终用户和应用）—2025-2032 年全球预测

Preterm Birth & PROM Testing Market by Product Type, End User, Application - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，早产和胎膜早破检测市场将成长 27 亿美元，复合年增长率为 6.42%。

主要市场统计数据
基准年2024年 16.4亿美元
预计2025年 17.4亿美元
预测年份：2032年 27亿美元
复合年增长率（%） 6.42%

动态介绍医疗保健领域早产和胎膜早破检测的临床重点、诊断工作流程和操作压力

早产和胎膜早破 (PROM) 检测处于产科、新生儿科和诊断创新的交叉领域。临床医生越来越依赖客观的生物标记和改进的检测工作流程来做出影响产妇和新生儿结局的时效性决策。同时，实验室主任和采购团队面临着在将新平台整合到现有诊断生态系统的同时，平衡准确性、通量和成本的压力。

在临床实践中，早期准确识别胎膜早破 (PROM) 和先兆早产可对诊疗路径产生重大影响，包括决定使用皮质类固醇、抗生素、强心剂以及转运至更高危重症中心。因此，能够在靠近患者和实验室的环境中提供快速可靠结果的创新技术正受到临床领导者的广泛关注。同时，监管审查和循证指南的更新正在重塑人们对检测验证、临床效用证明和上市后监测的期望。

从操作角度来看，诊断领域正朝着模组化工作流程发展，以支援周产期，对于实施具有临床意义且操作永续的检测通讯协定至关重要。总而言之，这些动态凸显了诊断检测创新在改善产前护理途径和减少后续新生儿併发症方面将发挥的关键作用。

技术、证据和供应链的最新变化如何重塑检测早产风险和胎膜早破的诊断策略

近年来，早产风险和胎膜早破（PROM）的识别、监测和管理方式发生了重大变化。分子诊断、免疫检测和照护现场技术的进步，在不牺牲分析性能的情况下实现了更快的反应时间。同时，数位健康平台和实验室资讯系统改进了数据集成，使临床医生能够将生物标记结果与电子健康记录趋势和决策支援演算法相结合。这些发展提高了临床医生对快速、可操作诊断结果的期望。

此外，诊断领域正更加重视临床效用和真实世界检验研究。开发者和应用者越来越多地寻求真实世界证据，将检测结果与患者管理和预后方面的可衡量变化联繫起来，而不是仅仅依赖实验室绩效指标。这种转变正在推动检测製造商和临床研究人员之间更紧密的合作，以设计能够证明有意义的临床终点的试验。

同时，供应链弹性和试剂永续性已成为策略重点。检测开发商正在投资试剂稳定性、替代筹资策略和耗材标准化，以减少营运中断。因此，采用决策不仅取决于分析准确性，还取决于长期供应的连续性和整合的便利性。这些综合变化正在重塑临床和实验室相关人员的产品蓝图和筹资策略。

了解不断变化的关税政策和进口成本压力将如何影响诊断测试供应链的弹性、采购策略以及 2025 年前的部署时间表

2025年的关税环境为诊断製造商、经销商和医疗保健采购组织带来了层层复杂性。更高的进口关税和关税分类的变化可能会增加仪器、套件和试剂的到岸成本，迫使组织重新评估筹资策略和供应商多元化。这促使一些製造商加快本地化生产或寻找替代供应商，以降低风险并保持利润率稳定。

采购领导者越来越关注总拥有成本 (TCO) 和合约机制，以规避关税波动的影响。例如，随着相关人员寻求可预测性，包含固定价格条款的多年期供应协议、联合库存规划以及在需求预测方面的密切合作已变得司空见惯。同时，诊断公司也在寻求关税工程——调整材料清单、组装流程、原产国文件等——以在不影响合规性的前提下最大限度地降低关税的影响。

重要的是，这些与关税相关的应对措施对临床部署週期产生了次要影响。设备出货前置作业时间延长以及试剂供应有限，可能会延迟诊断实验室的验证活动，并减缓新检测在门诊和住院环境中的部署。因此，卫生系统和实验室越来越重视紧急时应对计画和灵活的验证通讯协定，以确保即使在供应链中断的情况下也能持续提供临床服务。这些调整正在重塑整个诊断生态系统的采购策略和创新时间表。

细分主导的洞察，了解产品架构、最终用户需求和应用优先顺序如何决定采用模式和筹资策略

详细的細項分析揭示了不同产品类型、最终用户和应用在技术采用和使用模式上的显着差异。按产品类型划分，自动化 ELISA 分析仪、免疫检测分析仪和 PCR 系统等仪器和设备通常优先用于高通量诊断实验室和大型医院系统，因为这些系统的通量、准确性以及与实验室自动化的整合至关重要。相较之下，ELISA套件、PCR 检测试剂检测套组和快速检测套组等试剂套件和检测方法的应用范围更为广泛。 ELISA 和 PCR套件套件通常支援集中式实验室工作流程，而快速检测套组则能够在门诊和医院分流中更贴近患者地做出决策。

试剂和耗材，包括抗体、缓衝液、培养基、酵素和探针，是经常性的营运支出，推动采购和库存策略的发展。门诊护理优先考虑易用性和速度，诊断实验室强调通量和分析稳定性，医院和诊所需要扩充性并与临床工作流程相容，而研究机构通常需要可客製化的试剂和灵活性来支援探索性检测。需求概况进一步细分：诊断案例要求监管级别的验证和可重复性，监测用例强调序列采样和纵向解读，研究用例优先考虑实验灵活性，而筛检则要求高通量、成本效益和最低的假阳性率。

总的来说，产品架构、最终用户操作限制和预期用途之间的相互作用将决定产品开发的优先顺序、市场区隔以及整个诊断价值链的商业伙伴关係关係结构。

区域诊断格局和医疗保健系统的细微差别影响了美洲、欧洲、中东和非洲地区以及亚太地区的采用、报销和部署策略

区域动态显着影响早产和胎膜早破检测的诊断采用途径、报销框架和途径整合。在美洲，临床决策受到私人和公共支付机构、区域卓越中心以及对医院和实验室整合的关注。这种环境有利于扩充性的设备平台和检验套件，这些试剂盒可在综合医疗系统中部署，同时也支持学术中心的社区创新。

欧洲、中东和非洲地区 (EMEA) 的特点是监管环境和医疗保健津贴模式各异，导致各国的采用率不一。虽然集中式报销系统和完善的临床指南正在加速许多西方市场采用经过验证的诊断检测，但在其他地区，由于医疗保健预算有限和物流障碍，低成本快速检测和本地化试剂解决方案受到青睐。此外，区域合作和跨境研究伙伴关係在证据产生和指南协调方面发挥着日益重要的作用。

亚太地区拥有蓬勃发展的高所得医疗保健体系和庞大的新兴市场。快速的都市化和孕产妇保健服务的普及，推动了对高通量实验室解决方案和分散式检查模式的需求。旨在加强周产期保健基础设施的本地製造地和政府支持的倡议正在加速产品本地化和官民合作关係。在所有地区，相关人员一致认为，需要临床效用证据、与护理途径的无缝整合以及具有韧性的供应链，以确保关键诊断检测的持续可及性。

竞争、伙伴关係策略和基于证据的差异化将决定哪些公司将在早产和胎膜早破诊断创新方面处于领先地位

早产和胎膜早破 (PROM) 检测领域的竞争动态由众多知名诊断製造商、专业试剂供应商以及将照护现场功能推向市场的敏捷创新者共同塑造。现有仪器製造商继续在平台可靠性、与实验室自动化的兼容性以及全球服务网络方面竞争，而新参与企业则凭藉利基检测化学技术、简化的用户界面和快速部署模式脱颖而出。仪器製造商和检测开发商之间的战略伙伴关係和共同开发契约正在不断增多，从而加快了市场准入速度并共用了监管途径。

那些拥有稳定品质、可靠供应链和临床实验室优化包装的试剂和耗材供应商正成为采购团队的首选。同时，投资临床检验计画并检验真实世界证据的公司不仅可以证明分析准确性，还可以证明其对治疗决策的可衡量影响，从而加速临床医生的采纳。此外，经销商关係、医院直销以及实验室网路协定等通路动态也会影响跨地区的覆盖范围和应用。

总体而言，竞争优势将越来越取决于将技术性能与营运弹性和基于证据的临床价值相结合的能力，这为能够整合整个诊断生态系统并在从部署到上市后监测的整个生命週期内为客户提供支援的公司创造了机会。

诊断製造商和医疗保健领导者制定了可行的策略重点，重点是验证、弹性供应链、灵活的商业模式和付款人参与

产业领导者应优先考虑多管齐下的策略，将产品创新与临床检验、供应链稳健性和付款人参与度结合。首先，投资于实用临床研究，以证明诊断结果如何改变管理决策并改善孕产妇和新生儿的预后，这对于确保临床医生的认可和支持报销讨论至关重要。此类研究的设计应考虑现实世界的工作流程，并结合多中心合作以增强普适性。

其次，透过双重采购、多元化生产地点以及对试剂长期稳定性的承诺来增强供应链的韧性，可以降低营运风险并增强客户信心。同时，提供灵活的商业模式，例如试剂即服务、试剂设备租赁协议或捆绑式实施包，可降低医疗保健系统和实验室的采用门槛。

第三，领导者应积极与付款方、指南制定机构和医院采购委员会合作，展示其超越检测准确性的价值提案，并强调在有证据支持的情况下，避免下游成本、降低新生儿发病率并改善护理路径。最后，培育可互通的平台和开放资料标准将有助于与医院系统的整合，并实现增值分析，从而增强检测结果的临床效用。透过采取这些互补的行动，製造商和相关人员可以加快采用速度，同时降低商业性和营运风险。

结合主要专家访谈、技术文献和临床文献整合的严格方法检验了诊断性能和实施考虑

本分析整合了同行评审的临床文献、监管指南文件、行业可用的技术规格以及对临床医生、实验室主任和采购专业人员的初步访谈。该方法优先考虑三角测量，将分析性能证据与从实际实践中获得的临床效用和操作实施的见解相结合。在与监管指南相关的方面，我们关注的是指南如何指导验证需求和上市后监管，而不是特定司法管辖区的合规性检查清单。

初步研究包括与产科、新生儿科、检验医学和医院营运专家进行的结构化访谈。次要研究包括关于检测性能的方法论论文、已发表的关于早产儿恢復（PROM）及其早产诊断相关结局的临床研究，以及详细说明平台功能和耗材要求的供应商技术文件。数据整合强调了不同资讯来源主题的一致性，并指出了存在分歧的领域，以突出不确定性和有针对性地产生证据的机会。

调查方法的局限性包括临床文献中研究设计和终点的差异性、不同地区采用途径的异质性以及可能改变采购奖励的政策动态变化。为了克服这些局限性，我们透过多位专家访谈检验了研究结果，并与产品技术文献进行了交叉引用，以确保充分体现实际采用方面的考虑。

对诊断创新、证据预期和业务重点的总结性综合，将决定早产和胎膜早破检测的未来发展方向

摘要，在技术进步、更高的证据期望和业务需求的推动下，早产和胎膜早破（PROM）检测的诊断领域正在迅速发展。临床医生和实验室负责人正在寻求不仅能证明分析可靠性，还能证明临床疗效并且能够无缝整合到护理路径中的诊断方法。供应链的连续性和与关税相关的成本压力正在推动采购和合约设计的策略转变，从而影响部署和检验的时间表。

细分洞察表明，仪器和高通量平台仍将是医院和实验室策略的核心，而套件和照护现场套件将扩大门诊和急诊分流的可及性。试剂和耗材将继续影响目前的采购动态，而诊断、监测、研究用途和筛检领域的应用将对验证和工作流程整合产生差异化的要求。从地理上看，报销、法律规范和区域製造能力的相互作用将继续创造多样化的采用路径。

对于寻求推进产前检测的利害关係人相关人员，强有力的临床检验、灵活透明的交付模式以及与支付方和指南委员会的密切合作是明确的优先事项。这些优先事项将决定哪些创新技术能够实现永续的临床应用，并改善孕产妇和新生儿的预后。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 在门诊护理中越来越多地采用快速床边生化标记进行早期胎膜早破检测
  • 将预测分析与远端胎儿监测平台结合，以评估早产风险
  • 用于筛检妊娠中期早产阻塞性卵巢症候群（PROM）的非侵入性蛋白质体学检测的开发和临床实施
  • 人工智慧超音波影像成像技术的投资正在增加，以提高早产预测的准确性
  • 扩展基于生物标记的家用检测套组，以便患者主导早期检测胎膜破裂风险
  • 监管核准趋势和不断演变的报销框架推动了高级 PROM 诊断的普及
  • 学术研究中心与诊断公司合作检验不同族群的新型早产生物标记物

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

第 8 章早产和胎膜早破检测市场（依产品类型）

  • 设备和设施
    • 全自动ELISA分析仪
    • 免疫检测分析仪
    • PCR体系
  • 套件和检测试剂套件
    • 酵素连结免疫吸附测定试剂套件
    • PCR检测套组
    • 快速检测套组
  • 试剂和耗材
    • 抗体
    • 缓衝液和介质
    • 酵素和探针

第九章早产及胎膜早破检测市场（依最终用户划分）

  • 门诊治疗
  • 诊断实验室
  • 医院和诊所
  • 研究机构

第 10 章早产和胎膜早破检测市场（按应用）

  • 诊断
  • 监控
  • 研究用途
  • 筛检

第 11 章早产和胎膜早破检测市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第 12 章早产和胎膜早破检测市场（按群体）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 13 章早产和胎膜早破检测市场（按国家）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十四章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Roche Diagnostics GmbH
    • Abbott Laboratories
    • Hologic, Inc.
    • Quidel Corporation
    • Danaher Corporation
    • Thermo Fisher Scientific Inc.
    • bioMerieux SA
    • Sekisui Medical Co., Ltd.
    • Sera Prognostics, Inc.
    • Rhomed SpA
Product Code: MRR-42653751E7E1

The Preterm Birth & PROM Testing Market is projected to grow by USD 2.70 billion at a CAGR of 6.42% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.64 billion
Estimated Year [2025] USD 1.74 billion
Forecast Year [2032] USD 2.70 billion
CAGR (%) 6.42%

A dynamic introduction to clinical priorities, diagnostic workflows, and operational pressures shaping preterm birth and PROM testing across healthcare settings

Preterm birth and premature rupture of membranes (PROM) testing sit at the intersection of obstetrics, neonatal care, and diagnostic innovation. Clinicians increasingly rely on objective biomarkers and improved testing workflows to make time-sensitive decisions that affect maternal and neonatal outcomes. Meanwhile, laboratory directors and procurement teams face mounting pressure to balance accuracy, throughput, and cost while integrating new platforms into existing diagnostic ecosystems.

In clinical practice, early and precise identification of PROM and imminent preterm delivery can materially influence treatment pathways, including administration of corticosteroids, antibiotics, tocolytics, and decisions regarding transfer to higher-acuity centers. As a result, innovations that deliver rapid, reliable results in near-patient and laboratory settings are drawing significant attention from clinical leaders. Concurrently, regulatory scrutiny and evidence-based guideline updates are reshaping the expectations for test validation, clinical utility demonstrations, and post-market surveillance.

From an operational perspective, the diagnostic landscape is evolving toward modular workflows that support high-volume laboratory automation as well as decentralized testing at ambulatory and hospital sites. Cross-disciplinary collaboration among obstetricians, perinatologists, laboratorians, and hospital administrators is becoming central to implementing testing protocols that are clinically meaningful and operationally sustainable. Taken together, these dynamics underscore the critical role of diagnostic testing innovation in improving prenatal care pathways and reducing downstream neonatal complications.

How recent technological, evidence, and supply chain shifts are reshaping diagnostic strategies for detecting preterm birth risks and premature rupture of membranes

Recent years have seen a transformative shift in how preterm birth risk and PROM are identified, monitored, and managed. Advances in molecular diagnostics, immunoassays, and point-of-care technologies have enabled faster turnaround times without sacrificing analytical performance. Concurrently, digital health platforms and laboratory information systems are improving data integration, enabling clinicians to combine biomarker results with electronic health record trends and decision support algorithms. These developments have collectively raised clinician expectations for rapid, actionable diagnostic outputs.

Moreover, the diagnostic community has moved toward greater emphasis on clinical utility and pragmatic validation studies. Rather than relying solely on laboratory performance metrics, developers and adopters increasingly demand real-world evidence that links test results to measurable changes in patient management and outcomes. This shift has prompted closer engagement between test manufacturers and clinical investigators to design studies that demonstrate meaningful clinical endpoints.

At the same time, supply chain resilience and reagent sustainability have emerged as strategic priorities. Test developers are investing in reagent stabilization, alternative sourcing strategies, and consumable standardization to reduce operational disruptions. Consequently, adoption decisions now factor not just analytical accuracy but also long-term supply continuity and integration ease. Together, these shifts are reshaping product roadmaps and procurement strategies across clinical and laboratory stakeholders.

Understanding how evolving tariff policies and import cost pressures in 2025 are impacting supply chain resilience, procurement tactics, and deployment timelines for diagnostic testing

The tariff environment entering into 2025 introduced a layer of complexity for diagnostic manufacturers, distributors, and healthcare purchasing organizations. Increased import duties and changes to customs classifications have the potential to elevate landed costs for instruments, kits, and reagents, prompting organizations to reassess sourcing strategies and supplier diversification. In response, some manufacturers accelerated localization of manufacturing or qualified alternate suppliers to mitigate exposure and preserve margin stability.

Procurement leaders have reacted by increasing focus on total cost of ownership and contractual mechanisms that hedge against tariff volatility. For example, multi-year supply agreements with fixed pricing clauses, joint inventory planning, and closer collaboration on demand forecasting have become more common as stakeholders seek predictability. In parallel, diagnostic companies have explored tariff engineering-adjusting bill of materials, assembly processes, or country-of-origin documentation-to minimize the tariff impact without compromising compliance.

Importantly, these tariff-related responses have secondary effects on clinical deployment cycles. Extended lead times for instrument shipments and constrained reagent availability can delay validation activities in diagnostic laboratories and slow rollout of new tests in ambulatory and hospital settings. Consequently, health systems and laboratories are placing greater emphasis on contingency planning and flexible validation protocols so clinical service continuity is preserved when supply chain interruptions occur. These adaptations are reshaping procurement playbooks and innovation timelines across the diagnostic ecosystem.

Segmentation-driven insights into how product architectures, end-user needs, and application priorities determine adoption patterns and procurement strategies

A granular segmentation analysis reveals meaningful differences in technology adoption and usage patterns across product types, end users, and applications. Within product types, instruments and equipment such as automated ELISA analyzers, immunoassay analyzers, and PCR systems are typically prioritized by high-throughput diagnostic laboratories and larger hospital systems where throughput, precision, and integration with laboratory automation are paramount. In contrast, kits and assay formats including ELISA kits, PCR test kits, and rapid test kits serve a broader array of settings; ELISA and PCR kits often underpin centralized laboratory workflows while rapid test kits enable near-patient decision-making in ambulatory care or hospital triage.

Reagents and consumables, encompassing antibodies, buffers and media, and enzymes and probes, represent the recurring operational spend that drives procurement and inventory strategies. End users differ in their procurement and validation imperatives: ambulatory care settings typically prioritize ease of use and rapid turnaround, diagnostic laboratories emphasize throughput and analytical robustness, hospitals and clinics require scalability and compatibility with clinical workflows, and research institutes often seek customizable reagents and the flexibility to support exploratory assays. Applications further segment the demand profile, as diagnostic use cases demand regulatory-grade validation and reproducibility, monitoring applications focus on serial sampling and longitudinal interpretation, research use prioritizes experimental flexibility, and screening requires high throughput, cost-effectiveness, and minimal false-positive rates.

Taken together, the interplay among product architecture, end-user operational constraints, and intended application informs product development priorities, go-to-market segmentation, and the structure of commercial partnerships across the diagnostic value chain.

Regional diagnostic landscapes and healthcare system nuances that shape adoption, reimbursement, and deployment strategies across the Americas, EMEA, and Asia-Pacific

Regional dynamics materially influence diagnostic adoption pathways, reimbursement frameworks, and pathway integration for preterm birth and PROM testing. In the Americas, clinical decision-making is shaped by a mix of private and public payers, regional centers of excellence, and a strong emphasis on hospital and laboratory consolidation. This environment favors scalable instrument platforms and validated kits that can be deployed across integrated health systems, while also supporting localized innovation in academic centers.

Europe, Middle East & Africa features diverse regulatory landscapes and variable healthcare funding models, which create heterogenous adoption rates across countries. In many Western European markets, centralized reimbursement and robust clinical guidelines accelerate uptake of validated diagnostic tests, whereas in other parts of the region, constrained healthcare budgets and logistical barriers prioritize low-cost rapid tests and locally adaptable reagent solutions. Additionally, regional collaborations and cross-border research partnerships are playing an increasing role in evidence generation and guideline harmonization.

Asia-Pacific encompasses a fast-adopting mix of high-income healthcare systems and large emerging markets, where rapid urbanization and expanding prenatal care access drive demand for both high-throughput laboratory solutions and decentralized testing models. Local manufacturing hubs and government-supported initiatives aimed at strengthening perinatal care infrastructures are accelerating product localization and public-private partnerships. Across all regions, stakeholders are converging on the need for evidence of clinical utility, seamless integration into care pathways, and resilient supply chains to ensure continuous access to critical diagnostic testing.

Competitive forces, partnership strategies, and evidence-driven differentiation that determine which companies lead in preterm birth and PROM diagnostic innovation

Competitive dynamics in the preterm birth and PROM testing space are shaped by a mix of established diagnostics companies, specialized reagent suppliers, and agile innovators bringing point-of-care capabilities to market. Incumbent instrument manufacturers continue to compete on platform reliability, laboratory automation compatibility, and global service networks, while newer entrants differentiate through niche assay chemistries, simplified user interfaces, and rapid deployment models. Strategic partnerships and co-development agreements between instrumentation firms and assay developers have increased, enabling faster market entry and shared regulatory pathways.

Reagent and consumable suppliers that demonstrate consistent quality, validated supply chains, and packaging formats optimized for clinical laboratories gain preference among procurement teams. Meanwhile, companies that invest in clinical validation programs and publish real-world evidence can accelerate clinician adoption by proving not only analytical accuracy but also measurable impact on care decisions. Additionally, channel dynamics such as distributor relationships, direct sales to hospitals, and laboratory network agreements influence reach and uptake across geographies.

Overall, competitive advantage increasingly depends on the ability to align technical performance with operational resilience and evidence-based clinical value, creating opportunities for firms that can integrate across the diagnostic ecosystem and support customers across the lifecycle from implementation to post-market surveillance.

Actionable strategic priorities for diagnostic manufacturers and healthcare leaders focused on validation, resilient supply chains, flexible commercial models, and payer engagement

Industry leaders should prioritize a multi-pronged strategy that aligns product innovation with clinical validation, supply chain robustness, and payer engagement. First, investing in pragmatic clinical studies that demonstrate how diagnostic results change management decisions and improve maternal and neonatal outcomes will be critical to securing clinician buy-in and supporting reimbursement discussions. These studies should be designed with real-world workflows in mind and incorporate multicenter collaborations to enhance generalizability.

Second, strengthening supply chain resilience through dual sourcing, geographic diversification of manufacturing, and longer-term reagent stability initiatives will reduce operational risk and improve customer confidence. In parallel, offering flexible commercial models-such as reagent-as-a-service, reagent rental agreements for instruments, or bundled implementation packages-can lower adoption barriers for health systems and laboratories.

Third, leaders should engage proactively with payers, guideline-setting bodies, and hospital procurement committees to demonstrate the value proposition beyond test accuracy, highlighting downstream cost avoidance, reduced neonatal morbidity, and improved care pathways where evidence supports those outcomes. Finally, fostering interoperable platforms and open data standards will ease integration with hospital systems and enable value-added analytics that amplify the clinical utility of test results. By pursuing these complementary actions, manufacturers and stakeholders can accelerate adoption while mitigating commercial and operational risks.

A rigorous methodology combining primary expert interviews, technical documentation, and clinical literature synthesis to validate diagnostic performance and implementation considerations

This analysis synthesizes peer-reviewed clinical literature, regulatory guidance documents, industry-available technical specifications, and primary interviews with clinicians, laboratory directors, and procurement professionals. The approach prioritized triangulation, combining evidence of analytical performance with insights about clinical utility and operational implementation drawn from real-world practice. Where regulatory guidance was relevant, interpretations focused on how guidance informs validation needs and post-market surveillance rather than on jurisdiction-specific compliance checklists.

Primary research included structured interviews with subject-matter experts across obstetrics, neonatology, clinical laboratory science, and hospital operations. Secondary research reviewed methodological papers on assay performance, published clinical studies examining outcomes related to PROM and preterm birth diagnostics, and supplier technical documentation that details platform capabilities and consumable requirements. Data synthesis emphasized thematic consistency across sources, and areas of divergent opinion are noted to highlight uncertainties and opportunities for targeted evidence generation.

Limitations of the methodology include variability in study designs and endpoints within the clinical literature, heterogeneity in local adoption pathways across regions, and evolving policy dynamics that may alter procurement incentives. To mitigate these limitations, findings were validated through multiple expert interviews and cross-checked against technical product literature to ensure that practical implementation considerations are well represented.

Concluding synthesis of diagnostic innovation, evidence expectations, and operational priorities that determine the future trajectory of preterm birth and PROM testing

In summary, the diagnostic landscape for preterm birth and PROM testing is undergoing rapid evolution driven by technological advances, higher evidentiary expectations, and operational imperatives. Clinicians and laboratory leaders are seeking diagnostics that deliver not only analytical reliability but also demonstrable clinical impact and seamless integration into care pathways. Supply chain continuity and tariff-related cost pressures are prompting strategic shifts in sourcing and contract design, affecting timelines for deployment and validation.

Segmentation insight indicates that instruments and high-throughput platforms will remain central to hospital and laboratory strategies, while rapid and point-of-care kits will expand access in ambulatory settings and emergency triage. Reagents and consumables continue to shape recurring procurement dynamics, and applications spanning diagnosis, monitoring, research use, and screening create differentiated requirements for validation and workflow integration. Regionally, the interplay of reimbursement, regulatory frameworks, and local manufacturing capacity will continue to produce heterogeneous adoption pathways.

For stakeholders intent on advancing prenatal diagnostics, the clear priorities are robust clinical validation, resilient and transparent supply models, and closer engagement with payers and guideline committees. These priorities will determine which innovations translate into sustainable clinical uptake and improved maternal and neonatal outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising adoption of rapid point-of-care biochemical markers for early PROM detection in outpatient settings
  • 5.2. Integration of telehealth fetal monitoring platforms with predictive analytics for preterm labor risk assessment
  • 5.3. Development and clinical adoption of non-invasive proteomic assays for second-trimester preterm PROM screening
  • 5.4. Growing investment in AI-driven ultrasound imaging enhancements to improve preterm birth prediction accuracy
  • 5.5. Expansion of biomarker-based home testing kits enabling patient-managed early detection of membrane rupture risk
  • 5.6. Regulatory approval trends and evolving reimbursement frameworks driving access to advanced PROM diagnostics
  • 5.7. Collaboration between academic research centers and diagnostic firms to validate novel preterm birth biomarkers in diverse populations

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Preterm Birth & PROM Testing Market, by Product Type

  • 8.1. Instruments & Equipment
    • 8.1.1. Automated Elisa Analyzers
    • 8.1.2. Immunoassay Analyzers
    • 8.1.3. Pcr Systems
  • 8.2. Kits & Assay Kits
    • 8.2.1. Elisa Kits
    • 8.2.2. Pcr Test Kits
    • 8.2.3. Rapid Test Kits
  • 8.3. Reagents & Consumables
    • 8.3.1. Antibodies
    • 8.3.2. Buffers & Media
    • 8.3.3. Enzymes & Probes

9. Preterm Birth & PROM Testing Market, by End User

  • 9.1. Ambulatory Care
  • 9.2. Diagnostic Laboratories
  • 9.3. Hospitals & Clinics
  • 9.4. Research Institutes

10. Preterm Birth & PROM Testing Market, by Application

  • 10.1. Diagnosis
  • 10.2. Monitoring
  • 10.3. Research Use
  • 10.4. Screening

11. Preterm Birth & PROM Testing Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Preterm Birth & PROM Testing Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Preterm Birth & PROM Testing Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Analysis
    • 14.3.1. Roche Diagnostics GmbH
    • 14.3.2. Abbott Laboratories
    • 14.3.3. Hologic, Inc.
    • 14.3.4. Quidel Corporation
    • 14.3.5. Danaher Corporation
    • 14.3.6. Thermo Fisher Scientific Inc.
    • 14.3.7. bioMerieux SA
    • 14.3.8. Sekisui Medical Co., Ltd.
    • 14.3.9. Sera Prognostics, Inc.
    • 14.3.10. Rhomed S.p.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. AMERICAS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. NORTH AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. LATIN AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. EUROPE, MIDDLE EAST & AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. EUROPE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. MIDDLE EAST PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASEAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GCC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPEAN UNION PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. BRICS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. G7 PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. NATO PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. PRETERM BIRTH & PROM TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 26. PRETERM BIRTH & PROM TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. PRETERM BIRTH & PROM TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY AUTOMATED ELISA ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY AUTOMATED ELISA ANALYZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY AUTOMATED ELISA ANALYZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY AUTOMATED ELISA ANALYZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY AUTOMATED ELISA ANALYZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY AUTOMATED ELISA ANALYZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PCR SYSTEMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PCR SYSTEMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PCR SYSTEMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PCR SYSTEMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PCR SYSTEMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PCR SYSTEMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY ELISA KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY ELISA KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY ELISA KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY ELISA KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY ELISA KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY ELISA KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PCR TEST KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PCR TEST KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PCR TEST KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PCR TEST KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PCR TEST KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PCR TEST KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY RAPID TEST KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY RAPID TEST KITS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY RAPID TEST KITS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY RAPID TEST KITS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY RAPID TEST KITS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY RAPID TEST KITS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BUFFERS & MEDIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BUFFERS & MEDIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BUFFERS & MEDIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BUFFERS & MEDIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BUFFERS & MEDIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY BUFFERS & MEDIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY ENZYMES & PROBES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY ENZYMES & PROBES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY ENZYMES & PROBES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY ENZYMES & PROBES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY ENZYMES & PROBES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY ENZYMES & PROBES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY AMBULATORY CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY AMBULATORY CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY AMBULATORY CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY AMBULATORY CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY AMBULATORY CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY AMBULATORY CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY DIAGNOSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY DIAGNOSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY DIAGNOSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY DIAGNOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY DIAGNOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY RESEARCH USE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY RESEARCH USE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY RESEARCH USE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY RESEARCH USE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY RESEARCH USE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY RESEARCH USE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. AMERICAS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 140. AMERICAS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 141. AMERICAS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 142. AMERICAS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 143. AMERICAS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2018-2024 (USD MILLION)
  • TABLE 144. AMERICAS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2025-2032 (USD MILLION)
  • TABLE 145. AMERICAS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2025-2032 (USD MILLION)
  • TABLE 147. AMERICAS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. NORTH AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 156. NORTH AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2018-2024 (USD MILLION)
  • TABLE 158. NORTH AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2025-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2018-2024 (USD MILLION)
  • TABLE 160. NORTH AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2025-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 162. NORTH AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 164. NORTH AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. LATIN AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 170. LATIN AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2018-2024 (USD MILLION)
  • TABLE 172. LATIN AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2025-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2018-2024 (USD MILLION)
  • TABLE 174. LATIN AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2025-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 176. LATIN AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 178. LATIN AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 180. LATIN AMERICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2018-2024 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2025-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2018-2024 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 209. MIDDLE EAST PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. MIDDLE EAST PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. MIDDLE EAST PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 212. MIDDLE EAST PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 213. MIDDLE EAST PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2018-2024 (USD MILLION)
  • TABLE 214. MIDDLE EAST PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2025-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2018-2024 (USD MILLION)
  • TABLE 216. MIDDLE EAST PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2025-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 218. MIDDLE EAST PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 220. MIDDLE EAST PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 222. MIDDLE EAST PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 223. AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2018-2024 (USD MILLION)
  • TABLE 228. AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2025-2032 (USD MILLION)
  • TABLE 229. AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2018-2024 (USD MILLION)
  • TABLE 230. AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2025-2032 (USD MILLION)
  • TABLE 231. AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 232. AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 233. AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 234. AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 235. AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 236. AFRICA PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 237. ASIA-PACIFIC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 238. ASIA-PACIFIC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 239. ASIA-PACIFIC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 240. ASIA-PACIFIC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 241. ASIA-PACIFIC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2018-2024 (USD MILLION)
  • TABLE 242. ASIA-PACIFIC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2025-2032 (USD MILLION)
  • TABLE 243. ASIA-PACIFIC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2018-2024 (USD MILLION)
  • TABLE 244. ASIA-PACIFIC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2025-2032 (USD MILLION)
  • TABLE 245. ASIA-PACIFIC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 246. ASIA-PACIFIC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 247. ASIA-PACIFIC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 248. ASIA-PACIFIC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL PRETERM BIRTH & PROM TESTING MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 253. ASEAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 254. ASEAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 255. ASEAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. ASEAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. ASEAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2018-2024 (USD MILLION)
  • TABLE 258. ASEAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2025-2032 (USD MILLION)
  • TABLE 259. ASEAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2018-2024 (USD MILLION)
  • TABLE 260. ASEAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2025-2032 (USD MILLION)
  • TABLE 261. ASEAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 262. ASEAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 263. ASEAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 264. ASEAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 265. ASEAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 266. ASEAN PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 267. GCC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 268. GCC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 269. GCC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 270. GCC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 271. GCC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2018-2024 (USD MILLION)
  • TABLE 272. GCC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2025-2032 (USD MILLION)
  • TABLE 273. GCC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2018-2024 (USD MILLION)
  • TABLE 274. GCC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2025-2032 (USD MILLION)
  • TABLE 275. GCC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 276. GCC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 277. GCC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 278. GCC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 279. GCC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 280. GCC PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPEAN UNION PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPEAN UNION PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPEAN UNION PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPEAN UNION PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPEAN UNION PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPEAN UNION PRETERM BIRTH & PROM TESTING MARKET SIZE, BY INSTRUMENTS & EQUIPMENT, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPEAN UNION PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPEAN UNION PRETERM BIRTH & PROM TESTING MARKET SIZE, BY KITS & ASSAY KITS, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPEAN UNION PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPEAN UNION PRETERM BIRTH & PROM TESTING MARKET SIZE, BY REAGENTS & CONSUMABLES, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPEAN UNION PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPEAN UNION PRETERM BIRTH & PROM TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPEAN UNION PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPEAN UNION PRETERM BIRTH & PROM TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 295. BRICS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 296. BRICS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 297. BRICS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. BRICS PRETERM BIRTH & PROM TESTING MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. BRIC